Treatment of Philadelphia‐negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors

2019 ◽  
Vol 37 (3) ◽  
pp. 291-295 ◽  
Author(s):  
Alessandro Andriani ◽  
Elena Elli ◽  
Giulio Trapè ◽  
Nicoletta Villivà ◽  
Luana Fianchi ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Myeloproliferative Neoplasms ◽  
Clinical Results ◽  
Blastic Phase

Clinical Results And Prognostic Factors for Thoracic Myelopathy Caused by Ossification of Yellow Ligament after Surgical Treatment

2014 ◽  
Vol 21 (3) ◽  
pp. 116
Author(s):  
Whoan Jeang Kim ◽  
Dae Geon Song ◽  
Kun Young Park ◽  
Je Yun Koo ◽  
Won Cho Kwon ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Surgical Treatment ◽  
Clinical Results ◽  
Thoracic Myelopathy

Comprehensive single institute experience with melanoma TIL: Long term clinical results, toxicity profile, and prognostic factors of response

2020 ◽  
Vol 59 (7) ◽  
pp. 736-744 ◽  
Author(s):  
Michal J. Besser ◽  
Orit Itzhaki ◽  
Guy Ben‐Betzalel ◽  
Douglas B. Zippel ◽  
Dragoslav Zikich ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Clinical Results ◽  
Toxicity Profile

Improved Survival in Chronic Myeloid Leukemia (CML) Since the Introductin of Imatinib Therapy - A Single Institution Historical Experience

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 2750-2750
Author(s):  
Hun Lee ◽  
Jorge E. Cortes ◽  
Susan O'Brien ◽  
Elias Jabbour ◽  
Guillermo Garcia-Manero ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Median Survival ◽  
Myeloid Leukemia ◽  
Research Funding ◽  
Chronic Phase ◽  
Imatinib Therapy ◽  
Blastic Phase ◽  
Group A ◽  
The Impact ◽  
Over Time

Abstract Abstract 2750 Background: Outcome of CML since introduction of imatinib therapy has improved. Aims: analyze improvement of CML outcome in different phases. Study Group: A total of 1,569 patients with CML referred since 1965, within 1 month from diagnosis, were reviewed and used to identify phase-specific prognostic factors: 1,148 chronic, 175 accelerated, 246 blastic. Results: The median survival was 8.9 years in chronic, 4.8 years in accelerated, and 6 months in blastic phase. In chronic phase, the 8-year survival was ≤ 15% before 1983, 42–65% from 1983 to 2000, and 87% since 2001 (Figure 1). Survival was worse in older patients (p=0.004), but less significant since 2001 (p=0.07). Survival by Sokal risk was significantly different before 2001 (p<0.001), but not since 2001 (p=0.4). In accelerated phase, survival improved over time (p<0.001); the 8-year survival in patients treated since 2001 was 75% (Figure 2). Survival by age was not different in years < 2001 (p=0.09), but was better since 2001 in patients ≤ 70 years (p=0.004). Multivariate analysis derived adverse factors since 2001: older age (p=0.049), increased marrow blasts (p=0.03). In blastic phase, the median survival improved over time (p<0.001), although it is only 7 months since 2001. Conclusions: Survival in CML significantly improved significantly since 2001, particularly so in chronic and accelerated phases. Imatinib therapy minimized the impact of known prognostic factors and Sokal risk in chronic phase, and accentuated the impact of age in accelerated and blastic phases. Disclosures: Cortes: Novartis: Consultancy; Novartis: Research Funding; BMS: Consultancy, Research Funding; Ariad: Consultancy, Research Funding; Pfizer: Consultancy, Research Funding. Kantarjian:Novartis: Consultancy; Novartis: Research Funding; Pfizer: Research Funding; BMS: Research Funding.

Sign in / Sign up

Export Citation Format

Share Document